VivaChek Laboratories Revenue and Competitors
Estimated Revenue & Valuation
- VivaChek Laboratories's estimated annual revenue is currently $13.6M per year.
- VivaChek Laboratories's estimated revenue per employee is $251,000
Employee Data
- VivaChek Laboratories has 54 Employees.
- VivaChek Laboratories grew their employee count by 10% last year.
VivaChek Laboratories's People
Name | Title | Email/Phone |
---|
VivaChek Laboratories Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $13.6M | 54 | 10% | N/A | N/A |
#2 | $12.6M | 50 | 11% | N/A | N/A |
#3 | $2968.6M | 11827 | 3% | N/A | N/A |
#4 | $297.9M | 1187 | 10% | N/A | N/A |
#5 | $72.5M | 289 | 30% | N/A | N/A |
#6 | $2.3M | 9 | 0% | N/A | N/A |
#7 | $12M | 48 | 17% | N/A | N/A |
#8 | $16.6M | 66 | 35% | N/A | N/A |
What Is VivaChek Laboratories?
VivaChek Biotech (Hangzhou) Co., Ltd. and VivaChek Laboratories, Inc. are under one group and we are a dynamic, professional and vibrant glucose meter and POCT manufacturer. We focus on SMBG (Self Monitoring of Blood Glucose) and POCT with various technology platform, and we are bringing more accurate and more user-friendly products. In VivaChek, we believe in Professionalism, Respect, Trust and Leadership. We are committed to become a global trustworthy POCT supplier, a company that we are proud of in our life. Professionalism and Efficiency make us different. With more than 15 years experience in research and development of glucose meter and POCT, we have our unique solutions for many technical points. The facility and manufacturing processes are designed to comply with the quality standards set by GMP, ISO, and the US FDA’s Quality System Regulations, to make sure the consistent high quality of products.
keywords:N/AN/A
Total Funding
54
Number of Employees
$13.6M
Revenue (est)
10%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $13.1M | 54 | 13% | N/A |
#2 | $13.1M | 54 | 6% | N/A |
#3 | $10.7M | 54 | 10% | N/A |
#4 | $15.8M | 54 | 50% | N/A |
#5 | $14.1M | 54 | 8% | N/A |